吡格列酮对DSS诱导的炎症性肠病小鼠血清TNF-α与hs-CRP水平的影响

发布时间：2018-10-26 11:44

【摘要】：目的观察吡格列酮对炎症性肠病小鼠血清肿瘤坏死因子-α(TNF-α)与高敏C反应蛋白(hs-CRP)水平的影响,探讨吡格列酮可能成为治疗炎症性肠病的药物及降低远期动脉粥样硬化的发病风险。方法清洁BALB/c小鼠随机分为3组,分别为正常组、模型组、吡格列酮药物干预组。采用3%DSS溶液制备炎症性肠病小鼠模型,在造模第2天开始给予吡格列酮25 mg/kg灌胃,每天一次,直至实验结束。治疗结束后,采用酶联免疫法(ELISA法)检测血清hs-CRP、TNF-α。结果与正常组相比较,模型组小鼠肠组织出现炎症性表现,且血清hs-CRP、TNF-α的水平均显著增高(P0.01);与模型组相比较,吡格列酮干预组小鼠肠道炎症表现明显减轻,且血清hs-CRP、TNF-α的水平均显著降低(P0.01)。结论吡格列酮能下调炎症性肠病小鼠TNF-α的表达,减轻肠道炎症性改变,并改善肠道组织形态结构,而发挥治疗,明显降低血清hs-CRP的水平,降低远期动脉粥样硬化的风险。
[Abstract]:Objective to observe the effect of pioglitazone on serum levels of tumor necrosis factor- 伪 (TNF- 伪) and Gao Min C-reactive protein (hs-CRP) in mice with inflammatory bowel disease. To explore the possibility of pioglitazone as a drug for inflammatory bowel disease and to reduce the risk of long-term atherosclerosis. Methods Clean BALB/c mice were randomly divided into 3 groups: normal group, model group and pioglitazone intervention group. The model of inflammatory bowel disease was established in mice with 3%DSS solution. Pioglitazone was given orally for 25 mg/kg on the second day until the end of the experiment. After treatment, serum hs-CRP,TNF- 伪 was detected by enzyme linked immunosorbent assay (ELISA). Results compared with the normal group, the intestinal tissue of the model group showed inflammatory manifestations, and the level of serum hs-CRP,TNF- 伪 increased significantly (P0.01). Compared with the model group, the intestinal inflammation in pioglitazone treated group was obviously alleviated, and the serum hs-CRP,TNF- 伪 level was significantly decreased (P0.01). Conclusion pioglitazone can down-regulate the expression of TNF- 伪 in mice with inflammatory bowel disease, alleviate the inflammatory changes in the intestine and improve the morphology of intestinal tissue. The treatment of pioglitazone can significantly reduce the level of serum hs-CRP. Reduce the risk of long-term atherosclerosis.
【作者单位】：山西医科大学第一医院;
【分类号】：R574

【共引文献】